Bank of Montreal’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-6,137
| Closed | -$259K | – | 4172 |
|
|
2024
Q2 | $259K | Buy |
+6,137
| New | +$262K | ﹤0.01% | 2832 |
|
|
2023
Q3 | – | Sell |
-4,739
| Closed | -$229K | – | 4146 |
|
|
2023
Q2 | $229K | Sell |
4,739
-49,668
| -91% | -$2.3M | ﹤0.01% | 3138 |
|
|
2023
Q1 | $2.18M | Buy |
+54,407
| New | +$2.33M | ﹤0.01% | 1656 |
|
|
2022
Q4 | – | Sell |
-111,336
| Closed | -$4.79K | – | 4229 |
|
|
2022
Q3 | $4.79K | Buy |
+111,336
| New | +$5.72M | ﹤0.01% | 1375 |
|
|
2022
Q2 | – | Sell |
-40,319
| Closed | -$2.93M | – | 4374 |
|
|
2022
Q1 | $2.93M | Buy |
40,319
+7,469
| +23% | +$520K | ﹤0.01% | 1719 |
|
|
2021
Q4 | $2.79M | Sell |
32,850
-409
| -1% | -$33.3K | ﹤0.01% | 1441 |
|
|
2021
Q3 | $2.89M | Buy |
33,259
+520
| +2% | +$47K | ﹤0.01% | 1893 |
|
|
2021
Q2 | $3.16M | Buy |
32,739
+28,678
| +706% | +$2.99M | ﹤0.01% | 1823 |
|
|
2021
Q1 | $432K | Sell |
4,061
-6,889
| -63% | -$938K | ﹤0.01% | 2731 |
|
|
2020
Q4 | $1.55M | Buy |
10,950
+7,022
| +179% | +$833K | ﹤0.01% | 1964 |
|
|
2020
Q3 | $349K | Sell |
3,928
-1,862
| -32% | -$154K | ﹤0.01% | 2487 |
|
|
2020
Q2 | $509K | Buy |
5,790
+5,127
| +773% | +$339K | ﹤0.01% | 2253 |
|
|
2020
Q1 | $33K | Sell |
663
-6,396
| -91% | -$332K | ﹤0.01% | 3072 |
|
|
2019
Q4 | $302K | Buy |
7,059
+1,906
| +37% | +$78.6K | ﹤0.01% | 2937 |
|
|
2019
Q3 | $220K | Buy |
5,153
+139
| +3% | +$7.55K | ﹤0.01% | 2849 |
|
|
2019
Q2 | $318K | Buy |
5,014
+4,454
| +795% | +$283K | ﹤0.01% | 2682 |
|
|
2019
Q1 | $39K | Sell |
560
-519
| -48% | -$29.7K | ﹤0.01% | 3440 |
|
|
2018
Q4 | $47K | Buy |
1,079
+542
| +101% | +$29.6K | ﹤0.01% | 3298 |
|
|
2018
Q3 | $41K | Sell |
537
-12
| -2% | -$976 | ﹤0.01% | 3474 |
|
|
2018
Q2 | $43K | Buy |
549
+334
| +155% | +$21.6K | ﹤0.01% | 3477 |
|
|
2018
Q1 | $11K | Sell |
215
-310
| -59% | -$15.6K | ﹤0.01% | 3737 |
|
|
2017
Q4 | $24K | Buy |
525
+179
| +52% | +$8.78K | ﹤0.01% | 3531 |
|
|
2017
Q3 | $18K | Sell |
346
-9,049
| -96% | -$536K | ﹤0.01% | 3554 |
|
|
2017
Q2 | $584K | Sell |
9,395
-92,208
| -91% | -$5.56M | ﹤0.01% | 2198 |
|
|
2017
Q1 | $6.89M | Buy |
101,603
+100,479
| +8,939% | +$7.66M | 0.01% | 945 |
|
|
2016
Q4 | $88K | Buy |
1,124
+710
| +171% | +$50.4K | ﹤0.01% | 2899 |
|
|
2016
Q3 | $29K | Buy |
414
+133
| +47% | +$8.49K | ﹤0.01% | 3217 |
|
|
2016
Q2 | $14K | Sell |
281
-365
| -57% | -$23.6K | ﹤0.01% | 3493 |
|
|
2016
Q1 | $42K | Sell |
646
-136
| -17% | -$8.9K | ﹤0.01% | 3120 |
|
|
2015
Q4 | $87K | Buy |
782
+161
| +26% | +$16.1K | ﹤0.01% | 2829 |
|
|
2015
Q3 | $60K | Buy |
621
+461
| +288% | +$52.8K | ﹤0.01% | 2851 |
|
|
2015
Q2 | $16K | Buy |
+160
| New | +$12.4K | ﹤0.01% | 3369 |
|
|
2014
Q3 | – | Sell |
-170
| Closed | -$8K | – | 4338 |
|
|
2014
Q2 | $8K | Buy |
+170
| New | +$7K | ﹤0.01% | 3969 |
|
Other funds holding RARE
RSCM
Bank of Montreal's RARE Position: Q3 2024 in Review
Bank of Montreal sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 6,137 shares — an estimated $259K sold.
Bank of Montreal first reported a position in RARE in Q2 2014 and held it in 33 quarters. The position peaked at $6.89M in Q1 2017. 301 funds tracked by Wall St. Rank hold RARE as of Q3 2024.
- Bank of Montreal reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
- Bank of Montreal sold 6,137 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $259K.
- Bank of Montreal first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and held it in 33 quarters.
- Bank of Montreal's Ultragenyx Pharmaceutical position peaked at $6.89M in Q1 2017.
- 301 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.
Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.